What Knight Therapeutics does

Knight Therapeutics Inc. is a pan-American (ex-US) specialty pharmaceutical company headquartered in Montreal, Canada, and listed on the Toronto Stock Exchange under the symbol GUD. The company acquires, in-licenses, and commercializes branded pharmaceutical products across Canada and Latin America through a network of wholly-owned country affiliates (United Medical Ltda. in Brazil, Grupo Biotoscana de Especialidad in Mexico, and Laboratorio LKM S.A. in Argentina) and distribution partnerships covering more than 12 countries. Knight's portfolio spans oncology (MINJUVI, Pemazyre), immunology and hematology (TAVALISSE, NIKTIMVO), central nervous system (JORNAY PM), dermatology (WYNZORA), and infectious diseases (IMPAVIDO, Ambisome, Akynzeo, Bapocil). The company's products are sourced through licensing agreements with originators such as Rigel Pharmaceuticals and Incyte, supplemented by acquisitions including the June 2025 purchase of Paladin Pharma Inc. for approximately $107 million.

Knight's business model is based on exclusive territorial licensing and commercialization rather than proprietary drug discovery. Revenue is generated through pharmaceutical product sales across Canadian and Latin American markets, milestone payments under licensing agreements, and selective out-licensing of rights (e.g., IMPAVIDO U.S. rights to Eton Pharmaceuticals). Pricing is determined through government tenders, pharmacy distribution, and healthcare system negotiations in each jurisdiction. The company reported FY2025 revenue of approximately $450 million and Q1 2026 revenue of $148.4 million, representing 69% year-over-year growth, with FY2026 guidance of $510-525 million. Adjusted EBITDA grew 130% YoY in Q1 2026, and Knight maintains a debt-to-equity ratio of 0.09 with a current ratio of 2.32, funded in part by a US$100-200 million revolving credit facility syndicated by National Bank of Canada, Citibank, CIBC, and TD Bank.

Name

Knight Therapeutics

Legal name

Knight Therapeutics Inc.

Website

https://gud-knight.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Knight Therapeutics is a pan-American (ex-US) specialty pharmaceutical company that acquires, in-licenses, and commercializes branded prescription drugs across Canada and Latin America through wholly-owned affiliates and distribution partners serving patients and healthcare providers in oncology, immunology, CNS, dermatology, and infectious diseases.

Ownership category

akta.pro rank

Headquarters

HQ city

Westmount

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical Product Sales: Knight generates revenue primarily through the sale of pharmaceutical products across Canada and Latin American markets. Revenue is driven by promoted products, acquired portfolios (Paladin, Sumitomo), and product launches. The company experienced 69% YoY revenue growth in Q1 2026.
2. Licensing and Distribution Rights: Knight acquires exclusive commercial rights for pharmaceutical products in specific territories (Canada, Latin America) and generates revenue through product sales and milestone payments under licensing agreements with original developers like Rigel Pharmaceuticals.
3. Technology Transfer/Out-licensing: Knight out-licenses products to other pharmaceutical companies for commercialization in specific markets, such as granting Eton Pharmaceuticals exclusive U.S. commercialization rights for IMPAVIDO, generating consideration for the transferred rights.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

No substantive information about the company's core offerings is available in the provided source content.

Product overview

Knight Therapeutics is a pan-American (ex-US) specialty pharmaceutical company that operates as a single unified pharmaceutical commercialization platform rather than a multi-module software product. The company acquires, in-licenses, and commercializes pharmaceutical products across Canada and Latin America through a network of country-specific affiliates. The portfolio includes branded drugs for oncology (MINJUVI®), immunology/hematology (TAVALISSE®, NIKTIMVO®), central nervous system (JORNAY PM™), dermatology (WYNZORA®), and infectious diseases (IMPAVIDO®, Ambisome). Knight's business model centers on bringing innovative pharmaceutical products to the Canadian and Latin American markets through regulatory approvals, licensing agreements with originators like Rigel Pharmaceuticals and Incyte, and strategic acquisitions including Paladin Pharma Inc.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 69% year-over-year revenue growth in Q1 2026
• +3 more outcomes

Segments1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Rigel PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerKnight holds exclusive licensing agreement for Latin America (acquired in 2022) for TAVALISSE (fostamatinib) for chronic immune thrombocytopenia treatment. Knight secured regulatory approvals in Mexico (2024) and Brazil (2026) with commercial launches underway.
• Eton PharmaceuticalscoreChannel Partner/ Reseller/ DistributorKnight granted Eton Pharmaceuticals exclusive U.S. commercialization rights for IMPAVIDO (miltefosine), the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis. Rights effective September 26, 2026.
• IncytecoreStrategic or Co-development PartnerUnder 2025 amended agreement, Incyte handles development and manufacturing while Knight manages regulatory approvals and distribution for NIKTIMVO (axatilimab) in Latin America.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Eurofarma Laboratórios: Brazilian-based multinational pharmaceutical company with a leading specialty and branded generics presence across Latin America, directly comparable to Knight's LATAM commercial scope.
• Aché Laboratórios: Major Brazilian pharmaceutical company with a broad specialty and branded prescription portfolio across Brazil and other Latin American markets, competing with Knight's affiliate network in the region.

Broad incumbents

• Hikma Pharmaceuticals: Multinational specialty and generic pharmaceutical company with a major presence across emerging markets including MENA and Latin America, operating branded and injectable franchises comparable to Knight's specialty focus.
• Perrigo Company: Specialty and consumer self-care pharmaceutical company with global distribution including Latin American markets, comparable to Knight as a multi-region specialty pharma operator with licensed brands.
• Teva Pharmaceutical Industries: Global pharmaceutical leader with significant specialty and generics operations across Latin America, providing scale competition to Knight in commercializing specialty assets in the region.
• Bausch Health Companies: Canadian-headquartered specialty pharmaceutical company with a substantial Latin American commercial footprint through Bausch + Lomb and legacy Valeant assets; comparable to Knight as a Canada-based specialty pharma operator with significant LATAM presence.

Direct peers

• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company focused on niche therapeutic areas with a distribution- and licensing-driven commercial model similar to Knight's pan-American platform.
• Cipher Pharmaceuticals: Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes prescription products in Canada and select international markets, sharing Knight's distribution-led business model and therapeutic-area focus.
• Medison Pharma: Global specialty pharmaceutical company focused on commercializing innovative therapies in Canada, Israel, and Central Europe through licensing and distribution partnerships, sharing Knight's license-and-distribute playbook.
• Acerus Pharmaceuticals: Canadian specialty pharmaceutical company that in-licenses and commercializes therapeutics for men's health and specialty indications, sharing Knight's Canadian distribution and licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/knight-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Knight Therapeutics